About: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

facility in Meldola, Italy

Attributes	Values
rdf:type	Item
description	facility in Meldola, Italy (en)
rdfs:label	Istituto Tumori della Romagna IRST (it) Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (en)
skos:prefLabel	Istituto Tumori della Romagna IRST (it) Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (en)
name	Istituto Tumori della Romagna IRST (it) Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (en)
ROR ID	wds:Q30282164-D77458FD-E495-4D4E-B4E7-057A2077A2AB
ROR ID	013wkc921
image	wds:Q30282164-53F06741-843B-4EAC-ACD0-9E17A354E939
instance of	wds:Q30282164-10FB0EF5-F867-49CF-B7AA-6740E1F5C96B wds:Q30282164-77015fac-4ac3-e8bb-c12d-c943e72782b7
image
instance of	facility organization
country	wds:Q30282164-94093DD1-344F-4C1F-9905-2EBF6A2DC468
country	Italy
number of hospital beds	wds:Q30282164-06F0541D-C117-421C-8935-24217BC02E5F
number of hospital beds	36 (xsd:decimal)
Google Knowledge Graph ID	wds:Q30282164-6E07EB30-1318-446C-B81B-744F477FAC32
Ringgold ID	wds:Q30282164-E5A40334-22FD-46A7-8DDB-86E0A104AB5F
Google Knowledge Graph ID	http://g.co/kg/g/11gl62ybpj
Google Knowledge Graph ID	/g/11gl62ybpj
Ringgold ID	124882
inception	wds:Q30282164-F729D209-EEF8-42E9-BFF9-577FDED81998
inception	2003-01-01 00:00:00Z (xsd:dateTime)
Commons category	wds:Q30282164-9b665b71-8ee6-4926-9c40-5831f35ddda9
Commons category	Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
skos:altLabel	IRST (en)
located in the adm...erritorial entity	wds:Q30282164-434066EE-E017-4C55-8EC3-D7F6C4B2A9FE
ISNI	wds:Q30282164-FF66F824-C3EB-4CFF-80E1-C98863B080C8
coordinate location	wds:Q30282164-C1E007C1-F0C5-43FE-9D65-CDBDF1290001
official website	wds:Q30282164-F73F4D66-2103-47B7-9BA8-76D229CF5672
located in the adm...erritorial entity	Meldola
ISNI	0000000417559177
coordinate location	POINT(12.064828 44.125269)
official website	http://www.irst.emr.it/
GRID ID	wds:Q30282164-A2901A0E-BEAC-475B-8C82-A7FA96EF989D
parent organization	wds:Q30282164-36A45C59-EF4D-48DD-8EB5-825B8BE384BC
GRID ID	grid.419563.c
parent organization	Istituto di ricovero e cura a carattere scientifico
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q30282164 Category:Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori https://it.wikipedia.org/wiki/Istituto_Scientifico_Romagnolo_per_lo_Studio_e_la_Cura_dei_Tumori
is affiliation of	Cristian Lolli
is affiliation of	wds:Q89154604-eef2815f-4d2d-6c1c-226a-e32e60360544
is research site of	A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma ItaliaN Observational Study of Patients With Acute Lymphoblastic Leukemia Treated With Anti-CD22 Immunoconjugate Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia Study of REGN2810 in Adults With Cervical Cancer Phase III Radium 223 mCRPC-PEACE III A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metas Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL An Efficacy Study Comparing Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Participants Who Have Progressed on Crizotinib Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer innovaTIL-01, Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer A Trial of Tisotumab Vedotin in Cervical Cancer An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) encorAfenib, biNimetinib and Cetuximab in Subjects witH previOusly Untreated BRAF-mutant ColoRectal Cancer A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Par A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies Emilia-Romagna Surgical Colorectal Cancer Audit- ESCA
is research site of	wds:Q63573590-38B74650-A414-46BC-A3B6-F389BD64156E wds:Q64188667-F990F605-26A7-422F-A8BE-42E38D74BBBD wds:Q63579714-E75D7D2E-104B-4156-ACE7-2E6272B7DC7E wds:Q63594854-B7ADC124-F2F5-4863-AEE9-F1A32B09C187 wds:Q64805813-A4403C49-0A77-4E18-9C92-9A642D656433 wds:Q65345895-8C38B8E3-98C7-46CA-9A3A-EF2BBCBE489A wds:Q65347988-F369D02D-C02C-4515-97C5-40365CE67BF8 wds:Q63336293-0D6E301D-12F4-4239-84FE-C1F8CBFD765D wds:Q64837308-78894018-EBA7-4529-B4D7-4B02FBE56F36 wds:Q64610579-446C5DF1-2CBF-4511-A732-12F4F424469D

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software